81 results
P
elderly individuals
I/C
sufficient dietary intake of vitamin K, insufficient dietary intake of vitamin K
O
risk of osteoarthritis (OA) and pathological joint features
P
patients with non-valvular atrial fibrillation (NVAF)
I/C
non-vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs)
O
left atrial thrombus (LAT) formation before cardioversion or catheter ablation
P
Sadeq A. Al-Maweri, Mohammed Nasser Alhajj, Esraa A. Deshisha, Ameera K. Alshafei, Azza I. Ahmed, Nada O. Almudayfi, Sara A. Alshammari, Alla Alsharif, Saba Kassim
I/C
Curcumin mouthwashes, Chlorhexidine
O
Plaque and gingivitis control
P
Cardiovascular disease
I/C
Vitamin K supplementation, No intervention
O
Related risk factors
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
plant hedgerows
I/C
installation of plant hedgerows, no plant hedgerows
O
soil organic matter (SOM) concentration, total N (TN) concentration, total P (SMD) concentration, alkali N concentration, available P concentration, readily available potassium (K) concentration, soil total K concentration
P
patients with bioprosthetic valves and atrial fibrillation
I/C
direct anticoagulants (DOACs), vitamin K antagonists (VKAs)
O
all-cause death, major bleeding, stroke or systemic embolism
P
patients undergoing transcatheter aortic valve implantation (TAVI) with concomitant indication of oral anticoagulation
I/C
direct oral anticoagulants (DOACs), vitamin K antagonist (VKA)
O
all-cause mortality, major and/or life-threatening bleeding, stroke
P
patients with atrial fibrillation, patients with venous thromboembolism (VTE) or pulmonary embolism (PE)
I/C
edoxaban, vitamin K antagonists (VKAs)
O
major or clinically relevant nonmajor bleeding events, any bleeding events, intracranial bleeding events, gastro-intestinal bleeding events, death from any cause, stroke, systemic embolic events
P
Vitamin K antagonist (VKA) reversal
I/C
Four-factor prothrombin complex concentrate (4F-PCC), Weight-based dose (WB)
O
Goal INR